Eye Meds Now

 Quick Ophthalmic Drug Search

231 items found
YUTIQ (fluocinolone acetone (0.18 mg) intravitreal implant)
Prescription
Injectable
Injectable Implant
Anti-inflammatory Corticosteroids
Indications/Usage:

Indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.


Typical Dosing:  

►Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, recommended:

  • For ophthalmic intravitreal injection.
  • YUTIQ is a non-bioerodible intravitreal implant in a drug delivery system containing 0.18 mg fluocinolone acetonide, designed to release fluocinolone acetonide at an initial rate of 0.25 mcg/day, and lasting 36 months.
  • Administration:
    • The intravitreal injection procedure should be carried out under aseptic conditions, which include use of sterile gloves, a sterile drape, a sterile caliper, and a sterile eyelid speculum (or equivalent).
    • Adequate anesthesia and a broad-spectrum microbicide should be given prior to the injection.
    • The injection procedure for YUTIQ is as follows:
      • Just prior to injection, administer topical and/or subconjunctival anesthesia at the injection site (inferotemporal quadrant recommended).
      • Administer 2-3 drops of a broad-spectrum microbicide into the lower fornix. The lids may be scrubbed with cotton-tipped applicators soaked with a broad-spectrum microbicide. Place a sterile lid speculum. Have the patient look up and apply additional microbicide solution to the injection site. Allow 30-60 seconds for the topical antiseptic to dry prior to injection of YUTIQ.
      • Optimal placement of YUTIQ is inferior to the optic disc and posterior to the equator of the eye. Measure 4 millimeters inferotemporal from the limbus with the aid of callipers for point of entry into the sclera.
      • Using sterile procedure, open the sterile foil pouch containing YUTIQ.
      • Remove the YUTIQ applicator from the sterile pouch by grasping the barrel of the applicator; do not grasp the plunger.
      • Remove the black plunger stop from the plunger.
      • Carefully remove the protective cap from the needle and inspect the needle tip to ensure it is not bent.
      • Remove the trombone wire from the distal end of the needle. Prior to injection, keep the applicator tip above the horizontal plane to ensure that the YUTIQ implant does not fall out of the applicator.
      • Gently displace the conjunctiva so that after withdrawing the needle, the conjunctival and scleral needle entry sites will not align. Care should be taken to avoid contact between the needle and the lid margin or lashes.
      • Insert the needle through the conjunctiva and sclera up to the positive stop of the applicator.
      • Depress the plunger at the back of the applicator fully to deliver the YUTIQ implant into the back of the eye.
      • Remove the YUTIQ applicator from the eye and discard in biohazard sharps container.
      • Remove the lid speculum and perform indirect ophthalmoscopy to verify adequate central retinal artery perfusion, absence of any other complications, and to verify the placement of the implant. Scleral depression may enhance visualisation of the implant. Immediate measurement of intraocular pressure (IOP) may be performed at the discretion of the ophthalmologist.
  • Following the injection, patients should be monitored for change in intraocular pressure and for endophthalmitis. Monitoring may consist of a check for perfusion of the optic nerve head immediately after the injection, tonometry within 30 minutes following the injection, and biomicroscopy between two and seven days following the injection. Patients should be instructed to report without delay any symptoms suggestive of endophthalmitis.

How Supplied:  
  • Sterile single use preloaded applicator supplied with 25 gauge needle

Preservatives:  

None listed in package insert.


Storage:  
  • Store between 59° – 86°F (15° – 30°C).


Special Purchasing Instructions: How to Purchase

ZADITOR (ketotifen (0.025%) ophthalmic solution)
Over the Counter
Topical
Ophthalmic Solution
Antihistamines and Mast Cell Stabilizer Combinations
Indications/Usage:

Used for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander.


Typical Dosing:  

 Itching due to pollen, ragweed, grass, animal hair and dander.

  • Adults and children  3 years of age:
    • Put 1 drop in the affected eye(s) twice daily, every 8 – 12 hours, no more than twice per day.
  • Children < 3 years of age:
    • Consult a doctor.

How Supplied:  
  • 5 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store between 39° – 77°F (4° – 25°C).


Assistance: Payment Assistance

ZERVIATE (cetirizine (0.24%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Antihistamines
Indications/Usage:

Indicated for the treatment of ocular itching associated with allergic conjunctivitis.


Typical Dosing:  

Itching associated with allergic conjunctivitis, recommended:

  • Instill 1 drop in each affected eye twice daily (approximately 8 hours apart).
  • The single-use containers are to be used immediately after opening and can be used to dose both eyes.
  • Discard the single-use container and any remaining contents after administration.

How Supplied:  
  • Multi dose bottle:
    • 5 mL bottles
    • 7.5 mL bottles
  • Single-use containers:
    • 30 single-use containers in 1 carton (0.2 mL each)

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 59° – 77°F (15° – 25°C).
  • Store single-use containers in the original foil pouch until ready to use.


Assistance: Payment Assistance

ZIOPTAN (tafluprost (0.0015%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Prostaglandin Analogs
Indications/Usage:

Indicated for reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.


Typical Dosing:  

Elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, recommended:

  • Instill 1 drop in the conjunctival sac of the affected eye(s) once daily in the evening.
  • The dose should not exceed once daily since it has been shown that more frequent administration of prostaglandin analogs may lessen the IOP-lowering effect.
  • Reduction of the IOP starts approximately 2 – 4 hours after the first administration with the maximum effect reached after 12 hours.
  • May be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than 1 topical ophthalmic product is being used, each one should be administered at least 5 minutes apart.
  • The solution from 1 individual unit is to be used immediately after opening for administration to one or both eyes. Since sterility cannot be maintained after the individual unit is opened, the remaining contents should be discarded immediately after administration.

How Supplied:  
  • 0.3 mL in 10 single-use containers per pouch

Preservatives:  

None listed in package insert.


Storage:  
  • Store refrigerated at 36º – 46°F (2º – 8°C).
  • During shipment ZIOPTAN® may be maintained at temperatures up to 104ºF (40ºC) for a period not exceeding 2 days.  Mail-order prescriptions received after two days of the dispensing date noted on the prescribing label should not be used.
  • Store in the original pouch.
  • After the pouch is opened, the single-use containers may be stored in the opened foil pouch for up to 30 days at room temperature 68º – 77°F (20º – 25°C).
  • Protect from moisture.
  • Write down the date you open the foil pouch in the space provided on the pouch. Discard any unused containers 30 days after first opening the pouch.


ZIRGAN (ganciclovir (0.15%) ophthalmic gel)
Prescription
Topical
Gel
Antivirals
Indications/Usage:

Indicated for the treatment of acute herpetic keratitis (dendritic ulcers).


Typical Dosing:  

Acute herpetic keratitis, recommended:

  • Instill 1 drop in the affected eye 5 times per day (approximately every 3 hours while awake) until the corneal ulcer heals, and then 1 drop 3 times per day for 7 days.

How Supplied:  
  • 5 g tubes

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 59° – 77°F (15° – 25°C).
  • Do not freeze.


Assistance: Payment Assistance

ZITHROMAX (azithromycin (250 mg; 500 mg; 600 mg) tablets; (100 mg/5 mL; 200 mg/5 mL) oral suspension)
Prescription
Oral
Oral Suspension
Tablets
Antibiotics
Indications/Usage:

Indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms: uncomplicated skin and skin structure infections in adults due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae. Abscesses usually require surgical drainage. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications.

This medication has a broad FDA approval for "skin and skin structure infections." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "skin and skin structure infections." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

►Skin/skin structure (uncomplicated): 

  • 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5.

►Inclusion (chlamydial) conjunctivitis:

  • 1000 mg single dose.

►Hordeolum:

  • 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5.
Dosing for inclusion (chlamydial) conjunctivitis and hordeolum are based on professional judgment. This is our medical opinion and may not be true in all clinical circumstances.

How Supplied:  
  • Tablets:
    • 250 mg tablets
    • 500 mg tablets
    • 600 mg tablets
  • Oral supension:
    • 100 mg/5 mL oral suspension (15 mL bottles)
    • 200 mg/5 mL oral suspension (15 mL, 22.5 mL, 30 mL bottles)

Preservatives:  

None listed in package insert.


Storage:  
  • Tablets:
    • Store at 59° – 86°F (15° – 30°C).
  • Suspension:
    • Store dry powder below 86°F (30°C).
    • Store constituted suspension between 41° – 86°F (5° – 30°C).
    • Discard when full dosing is completed.


ZOVIRAX (acyclovir (200 mg) capsules; (400 mg; 800 mg) tablets; (200 mg/5 mL) oral suspension)
Prescription
Oral
Capsules
Oral Suspension
Tablets
Antivirals
Indications/Usage:

Indicated for the acute treatment of herpes zoster (shingles) and for the treatment of chickenpox (varicella).


Typical Dosing:  

►Herpes zoster (acute):

  • 800 mg every 4 hours orally, 5 times daily for 7 – 10 days.

Herpes simplex keratitis (acute):

  • Adults:
    • 400 mg orally 5 times daily for 7 – 10 days.
  • Children:
    • 12 – 15 mg/kg/day in divided doses for 7 – 10 days.

Herpes simplex keratitis (prophylaxis):

  • Adults:
    • 400 mg orally twice daily after recurrent bouts of herpes simplex keratitis.

Chickenpox:

  • Children ( 2 years of age):
    • 20 mg/kg per dose orally 4 times daily (80 mg/kg/day) for 5 days. Children over 40 kg should receive the adult dose for chickenpox.
  • Adults and children > 40 kg: 
    • 800 mg 4 times daily for 5 days.
    • Intravenous ZOVIRAX is indicated for the treatment of varicella-zoster infections in immunocompromised patients.
    • When therapy is indicated, it should be initiated at the earliest sign or symptom of chickenpox. There is no information about the efficacy of therapy initiated more than 24 hours after onset of signs and symptoms.

Additional information for Renal Impairment is in Notes below.

Dosing for herpes simplex keratitis is based on professional judgment. This is our medical opinion and may not be true in all clinical circumstances.

How Supplied:  
  • Capsules:
    • 200 mg capsules
  • Tablets:
    • 400 mg tablets
    • 800 mg tablets
  • Oral suspension:
    • 200 mg/5 mL oral suspension (473 mL bottles)

Preservatives:  

None listed in package insert (capsules, tablets); methylparaben, propylparaben (oral suspension)


Storage:  
  • Store at 59° – 77°F (15° – 25°C).
  • Protect tablets and capsules from moisture.


ZYLET (loteprednol etabonate (0.5%) – tobramycin (0.3%) ophthalmic suspension)
Prescription
Topical
Ophthalmic Suspension
Antibiotic–Steroid Combination Medications
Indications/Usage:

Indicated for use as a topical anti-infective and corticosteroid combination for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.

Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies.

The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye.

The particular anti-infective drug in this product (tobramycin) is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulasenegative), including penicillin-resistant strains. Streptococci, including some of the Group Abeta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae, and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species.

This medication has a broad FDA approval for "inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe." We have linked this medication with conditions we understand to be categorized as "inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

Steroid-responsive inflammatory ocular conditions, recommended:

  • Apply 1 – 2 drops of ZYLET® into the conjunctival sac of the affected eye every 4 – 6 hours. During the initial 24 – 48 hours, the dosing may be increased, to every 1 – 2 hours.
  • Frequency should be decreased gradually as warranted by improvement in clinical signs.
  • Care should be taken not to discontinue therapy prematurely.
  • Not more than 20 mL should be prescribed initially and the prescription should not be refilled without further evaluation [See Warnings and Precautions (5.3) in package insert].

How Supplied:  
  • 5 mL bottles
  • 10 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store upright at 59º – 77ºF (15º – 25ºC).
  • Protect from freezing.
  • Shake vigorously before using.


Assistance: Payment Assistance

ZYMAXID (gatifloxacin (0.5%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Antibiotics
Indications/Usage:

Indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Aerobic gram-positive bacteria: Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus mitis group*; Streptococcus oralis*; Streptococcus pneumoniae. Aerobic gram-negative bacteria: Haemophilus influenzae.

*Efficacy for this organism was studied in fewer than 10 infections.


Typical Dosing:  

►Bacterial conjunctivitis caused by susceptible strains of listed organisms:

  •  Patients  1 year of age: 
    • Instill 1 drop every 2 hours in the affected eye(s) while awake, up to 8 times on day 1.
    • Instill 1 drop 2 – 4 times daily in the affected eye(s) while awake on days 2 – 7.

 

►Recurrent corneal erosion:

  • Follow normal dosing patterns.

How Supplied:  
  • 2.5 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 59° – 77°F (15° – 25°C).
  • Protect from freezing.


Assistance: Payment Assistance

ZYRTEC (cetirizine hydrochloride (10 mg) capsules, liquid filled; (10 mg) tablets, orally disintegrating; (10 mg) tablets)
Over the Counter
Oral
Capsules
Oral Disintegrating Tablets
Tablets
Antihistamines
Indications/Usage:

Used for the temporary relief of the following symptoms due to hay fever or other upper respiratory allergies: runny nose; sneezing; itchy, watery eyes; itching of the nose or throat.


Typical Dosing:  

►Runny nose; sneezing; itchy, watery eyes; itching of the nose or throat:

  • Adults and children 6 years of age:
    • One 10 mg capsule or tablet once a day.
    • A 5 mg product may be appropriate for less severe symptoms.
    • Do not take more than one 10 mg capsule or tablet in 24 hours.
    • Orally disintegrating tablet melts in mouth. Can be taken with or without water.
  • Adults  65 years of age:
    • Ask a doctor.
  • Children < 6 years of age: 
    • Ask a doctor.
  • Individuals with liver or kidney disease:
    • Ask a doctor.

How Supplied:  
  • Capsules:
    • 10 mg capsules
  • Tablets, orally disintegrating:
    • 10 mg orally disintegrating tablets
  • Tablets:
    • 10 mg tablets

Preservatives:  

None listed in package insert.


Storage:  
  • Store at 68° – 77°F (20° – 25°C).
  • Avoid high humidity and excessive heat above 104°F (40°C).
  • Protect from light.


ZYRTEC CHILDREN'S (cetirizine hydrochloride (5 mg/5 mL) oral solution; (10 mg) tablets, orally disintegrating)
Over the Counter
Oral
Oral Disintegrating Tablets
Oral Solution
Antihistamines
Indications/Usage:

Used for the temporary relief of the following symptoms due to hay fever or other upper respiratory allergies: runny nose; sneezing; itchy, watery eyes; itching of the nose or throat.


Typical Dosing:  

►Runny nose; sneezing; itchy, watery eyes; itching of the nose or throat:

  • Tablets, orally disintegrating:
    • Adults and children 6 years of age:
      • One 10 mg tablet once a day.
      • A 5 mg product may be appropriate for less severe symptoms.
      • Do not take more than one 10 mg tablet in 24 hours.
      • Orally disintegrating tablet melts in mouth. Can be taken with or without water.
    • Adults  65 years of age:
      • Ask a doctor.
    • Children 6 years of age: 
      • Ask a doctor.
    • Individuals with liver or kidney disease:
      • Ask a doctor.
  • Oral solution:
    • Adults and children 6 years of age:
      • 5 mL or 10 mL once a day depending upon severity of symptoms.
      • Do not take more than 10 mL in 24 hours.
    • Adults  65 years of age:
      • 5 mL once a day.
      • Do not take more than 5 mL in 24 hours.
    • Children 2 to 6 years of age: 
      • 2.5 mL once daily. If needed, dose can be increased to a maximum of 5 mL once daily or 2.5 mL every 12 hours.
      • Do not give more than 5 mL in 24 hours.
    • Children 2 years of age: 
      • Ask a doctor.
    • Individuals with liver or kidney disease:
      • Ask a doctor.
    • Use only with enclosed dosing cup.

How Supplied:  
  • Oral solution:
    • 5 mg/5 mL oral solution
  • Tablets, orally disintegrating:
    • 10 mg orally disintegrating tablets

Preservatives:  

None listed in package insert (tablets); sodium benzoate (oral solution)


Storage:  
  • Store at 68° – 77°F (20° – 25°C).
  • Avoid high humidity and excessive heat above 104°F (40°C).
  • Protect from light.


231 items found